EICHOR
● Active Not Recruiting
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
Condition: Dry Eye Disease · Sponsor: AbbVie
About this study
Dry Eye Disease (DED) refers to a long-term condition that happens when there is not enough lubrication in your eyes. This can happen when your eye cannot make enough tears or if you make poor-quality tears. The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (ABBV-444) with Refresh Optive UD for 90 days in participants with Dry Eye Disease (DED. ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). Participants will be placed into 1 of 2 treatment arms. Each group receives different treatment. Adult participants diagnosed with dry eye disease will be enrolled. Around 250 participants will be enrolled in the study at approximately 20 sites across the US In this study, participants first complete a 7-day run-in period using REFRESH PLUS® eye drops. Those eligible are then randomized to receive ABBV-444 eye drops or REFRESH OPTIVE® Unit Dose eye drops. Participants in both arms will receive treatment for a 90-day treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend multiple required study visits during the study at the study site. The effect of the treatment will be checked by medical assessments and questionnaires.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (20)
| Trinity Research Group /ID# 279914 | Dothan, Alabama, United States | — |
| Arizona Eye Center - West Ray Road /ID# 267993 | Chandler, Arizona, United States | — |
| Canyon City Eyecare /ID# 267948 | Azusa, California, United States | — |
| Global Research Management /ID# 267980 | Glendale, California, United States | — |
| Lakeside Vision Center /ID# 268544 | Irvine, California, United States | — |
| Eye Research Foundation /ID# 267931 | Newport Beach, California, United States | — |
| Lee Shettle Eye and Hearing /ID# 268118 | Largo, Florida, United States | — |
| Clayton Eye Center /ID# 268097 | Morrow, Georgia, United States | — |
| Coastal Research Associates - Roswell /ID# 279915 | Roswell, Georgia, United States | — |
| Kannarr Eye Care /ID# 267979 | Pittsburg, Kansas, United States | — |
| Butchertown Clinical Trials /ID# 267887 | Louisville, Kentucky, United States | — |
| Moyes Eye Centers /ID# 267944 | Kansas City, Missouri, United States | — |
+ 8 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07284381